BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 37573801)

  • 1. Robotic surgery in ovarian cancer.
    Gallotta V; Certelli C; Oliva R; Rosati A; Federico A; Loverro M; Lodoli C; Foschi N; Lathouras K; Fagotti A; Scambia G
    Best Pract Res Clin Obstet Gynaecol; 2023 Aug; 90():102391. PubMed ID: 37573801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating robotic surgery into the management of ovarian cancer after neoadjuvant chemotherapy.
    Abitbol J; Gotlieb W; Zeng Z; Ramanakumar A; Kessous R; Kogan L; Pare-Miron V; Rombaldi M; Salvador S; Kucukyazici B; Brin S; How J; Lau S
    Int J Gynecol Cancer; 2019 Nov; 29(9):1341-1347. PubMed ID: 31601648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. When Less Is More: Minimally Invasive Surgery Compared with Laparotomy for Interval Debulking After Neoadjuvant Chemotherapy in Women with Advanced Ovarian Cancer.
    Brown J; Drury L; Crane EK; Anderson WE; Tait DL; Higgins RV; Naumann RW
    J Minim Invasive Gynecol; 2019; 26(5):902-909. PubMed ID: 30240899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robotic interval debulking surgery for advanced epithelial ovarian cancer: current challenge or future direction? A systematic review.
    Psomiadou V; Prodromidou A; Fotiou A; Lekka S; Iavazzo C
    J Robot Surg; 2021 Apr; 15(2):155-163. PubMed ID: 33037532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Minimally invasive secondary cytoreduction plus HIPEC versus open surgery plus HIPEC in isolated relapse from ovarian cancer: a retrospective cohort study on perioperative outcomes.
    Fagotti A; Costantini B; Gallotta V; Cianci S; Ronsini C; Petrillo M; Pacciani M; Scambia G; Fanfani F
    J Minim Invasive Gynecol; 2015; 22(3):428-32. PubMed ID: 25461683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival outcomes after delayed cytoreduction surgery following neoadjuvant chemotherapy in advanced epithelial ovarian cancer.
    Yao SE; Tripcony L; Sanday K; Robertson J; Perrin L; Chetty N; Land R; Garrett A; Obermair A; Nascimento M; Tang A; Jagasia N; Singh P; Nicklin J
    Int J Gynecol Cancer; 2020 Dec; 30(12):1935-1942. PubMed ID: 33122245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing feasibility and perioperative outcomes with minimally invasive surgery compared with laparotomy for interval debulking surgery with hyperthermic intraperitoneal chemotherapy for advanced epithelial ovarian cancer.
    Morton M; Chambers LM; Costales AB; Chichura A; Gruner M; Horowitz MP; Rose PG; Yao M; Debernardo R; Michener C
    Gynecol Oncol; 2021 Jan; 160(1):45-50. PubMed ID: 33067001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Robotic surgery in early and advanced ovarian cancer: Case selection for surgical staging and interval debulking surgery.
    Van Trappen P; de Cuypere E; Claes N
    Eur J Obstet Gynecol Reprod Biol; 2023 Jan; 280():7-11. PubMed ID: 36371963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing Laparotomy with Robot-assisted Interval Debulking Surgery for Patients with Advanced Epithelial Ovarian Cancer Receiving Neoadjuvant Chemotherapy.
    Zhang Y; Grant MS; Zhang X; Paraghamian SE; Tan X; Clark LH
    J Minim Invasive Gynecol; 2021 Jun; 28(6):1237-1243. PubMed ID: 33248314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of secondary cytoreductive surgery in platinum sensitive recurrent ovarian cancer treated with upfront neoadjuvant chemotherapy and interval debulking surgery.
    Bizzarri N; Marchetti C; Conte C; Loverro M; Giudice MT; Quagliozzi L; Distefano M; Chiantera V; Scambia G; Fagotti A
    Gynecol Oncol; 2022 Jun; 165(3):453-458. PubMed ID: 35397918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis.
    Knisely A; Gamble CR; St Clair CM; Hou JY; Khoury-Collado F; Gockley AA; Wright JD; Melamed A
    J Minim Invasive Gynecol; 2021 Mar; 28(3):537-543. PubMed ID: 33202311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy.
    Kumari A; Thakur M; Saha SC; Suri V; Prasad GRV; Patel FD; Radhika S
    J Obstet Gynaecol; 2021 May; 41(4):616-620. PubMed ID: 32811236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer.
    Menderes G; Black JD; Azodi M
    Expert Rev Anticancer Ther; 2016 Sep; 16(9):899-901. PubMed ID: 27477495
    [No Abstract]   [Full Text] [Related]  

  • 15. A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.
    Ghisoni E; Katsaros D; Maggiorotto F; Aglietta M; Vaira M; De Simone M; Mittica G; Giannone G; Robella M; Genta S; Lucchino F; Marocco F; Borella F; Valabrega G; Ponzone R
    J Ovarian Res; 2018 May; 11(1):42. PubMed ID: 29843747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prise en charge chirurgicale du cancer épithélial de l'ovaire - première ligne et première rechute: Surgical management of epithelial ovarian cancer - first line and first relapse.
    Classe JM; Joly F; Lécuru F; Morice P; Pomel C; Selle F; You B
    Bull Cancer; 2021 Dec; 108(9S1):S13-S21. PubMed ID: 34955158
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Epithelial ovarian cancers and minimally invasive cytoreductive surgery after neoadjuvant chemotherapy: A systematic review].
    Achen G; Koual M; Bentivegna E; Fournier L; Nguyen Xuan HT; Delanoy N; Bats AS; Azaïs H
    Gynecol Obstet Fertil Senol; 2021 Oct; 49(10):736-743. PubMed ID: 33636412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.
    Perrone AM; Coada CA; Ravegnini G; De Leo A; Damiano G; De Crescenzo E; Tesei M; Di Costanzo S; Genovesi L; Rubino D; Zamagni C; De Iaco P
    Int J Gynecol Cancer; 2023 Aug; 33(8):1270-1278. PubMed ID: 37429642
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical complexity score and role of laparoscopy in women with advanced ovarian cancer treated with neoadjuvant chemotherapy.
    Davidson BA; Broadwater G; Crim A; Boccacio R; Bixel K; Backes F; Previs RA; Salinaro J; Salani R; Moore K; Secord AA
    Gynecol Oncol; 2019 Mar; 152(3):554-559. PubMed ID: 30558972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.